Jiang Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiang Zhu has a total of 184 co-authors. Here are the top co-authors by number of shared publications:
Wu Zhang
State Key Laboratory for Medical Genomics, Shanghai Institute of Hematology and Collaborative Innovation Center of Hematology, Rui-Jin Hospital Affiliated to Shanghai Jiao-Tong University School of Medicine, Shanghai, People’s Republic of China
10 shared publicationsJuan Chen
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital affiliated to Shanghai Jiao-Tong University School of Medicine
7 shared publications- Sai-Juan Chen
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 shared publications - Zhu Chen
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 shared publications He-Zhou Guo
Department of Hematology, Shanghai Ninth People's Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao-Tong University School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao-Tong University, Shanghai, China
5 shared publicationsShijun Chen
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital affiliated to Shanghai Jiao-Tong University School of Medicine
5 shared publications
Latest Publications
- Open Access
- 16 January 2026
- Published by Springer Nature in Research Square
Partial differentiation induction of leukemia cells co-opts NK cells to erode leukemic stemness
ATRA-induced granulocytic differentiation of acute promyelocytic leukemia (APL) cells is thought to underpin high-rate cure of this disease. Yet, how differentiation induction affects leukemic stemness remains undetermined. To address this, we employed flow cytometry- and scRNA-seq-based leukemic subset dissection and functional assays to characterize APL hierarchy, revealing a particular structure wherein apical leukemic progenitors underwent multitiered and lineage-branching differentiation into monocytic and/or granulocytic directions, which was dynamically modulated by different treatments. Notably, ATRA shifted APL hierarchy towards granulocytic differentiation but inefficiently generated terminal granulocytes, leaving relative persistence of intermediate differentiating subsets that retained certain leukemia-initiating cell (LIC) potential. Nevertheless, ATRA rendered most of the intermediate c-Kit −/lo granulocytic LICs more vulnerable to endogenous CD62L + NK subset-mediated immunorejection. Thus, our observations demonstrate that ATRA-triggered LIC erosion critically depends on NK immunity rather than on APL cells’ entry into terminal maturation.
- 16 January 2026
- Published by Springer Nature in Research Square
Open AccessPartial differentiation induction of leukemia cells co-opts NK cells to erode leukemic stemness
ATRA-induced granulocytic differentiation of acute promyelocytic leukemia (APL) cells is thought to underpin high-rate cure of this disease. Yet, how differentiation induction affects leukemic stemness remains undetermined. To address this, we employed flow cytometry- and scRNA-seq-based leukemic subset dissection and functional assays to characterize APL hierarchy, revealing a particular structure wherein apical leukemic progenitors underwent multitiered and lineage-branching differentiation into monocytic and/or granulocytic directions, which was dynamically modulated by different treatments. Notably, ATRA shifted APL hierarchy towards granulocytic differentiation but inefficiently generated terminal granulocytes, leaving relative persistence of intermediate differentiating subsets that retained certain leukemia-initiating cell (LIC) potential. Nevertheless, ATRA rendered most of the intermediate c-Kit −/lo granulocytic LICs more vulnerable to endogenous CD62L + NK subset-mediated immunorejection. Thus, our observations demonstrate that ATRA-triggered LIC erosion critically depends on NK immunity rather than on APL cells’ entry into terminal maturation.
- Open Access
- 14 September 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (11) , 5074-5078
Systemic and dynamic immune landscape of Omicron-infected subjects treated with Lianhua Qingwen capsules
- 14 September 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (11) , 5074-5078
Open AccessSystemic and dynamic immune landscape of Omicron-infected subjects treated with Lianhua Qingwen capsules
- Open Access
- 5 June 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (6) , 101592
A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML
- 5 June 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (6) , 101592
Open AccessA CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML
- Open Access
- 15 January 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (1) , e1530
The roles of innate and adaptive immunity in inactivated viral vaccination‐mediated protection against COVID‐19
- 15 January 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (1) , e1530
Open AccessThe roles of innate and adaptive immunity in inactivated viral vaccination‐mediated protection against COVID‐19
- Open Access
- 1 May 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (9)
Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells
Antitumor activity of CD8+ T cells is potentially restrained by a variety of negative regulatory pathways that are triggered in the tumor microenvironment, yet, the exact mechanisms remain incompletely defined. Here, we report that intrinsic RIG-I in CD8+ T cells represents such a factor, as evidenced by observations that the tumor-restricting effect of endogenous or adoptively transferred CD8+ T cells was enhanced by intrinsic Rig-I deficiency or inhibition, with the increased accumulation, survival, and cytotoxicity of tumor-infiltrating CD8+ T cells. Mechanistically, T cell activation–induced RIG-I upregulation restrained STAT5 activation via competitive sequestering of HSP90. In accordance with this, the frequency of RIG-I+ tumor-infiltrating CD8+ T cells in human colon cancer positively correlated with attenuated survival and effector signatures of CD8+ T cells as well as poor prognosis. Collectively, these results implicate RIG-I as a potentially druggable factor for improving CD8+ T cell–based tumor immunotherapy.
- 1 May 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (9)
Open AccessIntrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells
Antitumor activity of CD8+ T cells is potentially restrained by a variety of negative regulatory pathways that are triggered in the tumor microenvironment, yet, the exact mechanisms remain incompletely defined. Here, we report that intrinsic RIG-I in CD8+ T cells represents such a factor, as evidenced by observations that the tumor-restricting effect of endogenous or adoptively transferred CD8+ T cells was enhanced by intrinsic Rig-I deficiency or inhibition, with the increased accumulation, survival, and cytotoxicity of tumor-infiltrating CD8+ T cells. Mechanistically, T cell activation–induced RIG-I upregulation restrained STAT5 activation via competitive sequestering of HSP90. In accordance with this, the frequency of RIG-I+ tumor-infiltrating CD8+ T cells in human colon cancer positively correlated with attenuated survival and effector signatures of CD8+ T cells as well as poor prognosis. Collectively, these results implicate RIG-I as a potentially druggable factor for improving CD8+ T cell–based tumor immunotherapy.
- Open Access
- 27 October 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-3
Author Correction: mTORC1 Maintains the Tumorigenicity of SSEA-4 + High-Grade Osteosarcoma
- 27 October 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-3
Open AccessAuthor Correction: mTORC1 Maintains the Tumorigenicity of SSEA-4 + High-Grade Osteosarcoma
- 14 October 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (42)
Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion
Significance: Application scope, underlying mechanisms, and potential limitation of AAV/CRISPR-mediated hepatic gene editing remain unexplored. Here we report that a synthetic enhancer/promoter (P2) incorporation empowered AAV/CRISPR to restore FIX-encoding capacity of a severe F9 defect involving the regulatory region. Systemic analyses revealed a critical role of host cell heterogenicity in determining the therapeutic benefit of this regimen, wherein a subclinical inflammation posttreatment regulated the P2 activity and the retention of the edited F9 alleles in a hepatocytic subset–dependent manner. Moreover, preeminent hepatic presence of hematopoietic cells implicated their involvement in fueling and restricting this hepatic inflammation. Collectively, these results characterize the critical factors determining the efficacy and durability of AAV/CRIPSR-mediated gene editing in dealing with complicated hepatic monogenic disorders.
- 14 October 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (42)
Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion
Significance: Application scope, underlying mechanisms, and potential limitation of AAV/CRISPR-mediated hepatic gene editing remain unexplored. Here we report that a synthetic enhancer/promoter (P2) incorporation empowered AAV/CRISPR to restore FIX-encoding capacity of a severe F9 defect involving the regulatory region. Systemic analyses revealed a critical role of host cell heterogenicity in determining the therapeutic benefit of this regimen, wherein a subclinical inflammation posttreatment regulated the P2 activity and the retention of the edited F9 alleles in a hepatocytic subset–dependent manner. Moreover, preeminent hepatic presence of hematopoietic cells implicated their involvement in fueling and restricting this hepatic inflammation. Collectively, these results characterize the critical factors determining the efficacy and durability of AAV/CRIPSR-mediated gene editing in dealing with complicated hepatic monogenic disorders.
- Open Access
- 8 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (41)
Leukemic progenitor cells enable immunosuppression and post-chemotherapy relapse via IL-36–inflammatory monocyte axis
A stimulated proinflammatory feature of leukemic progenitors facilitates their survival and immune evasion after chemotherapy.
- 8 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (41)
Open AccessLeukemic progenitor cells enable immunosuppression and post-chemotherapy relapse via IL-36–inflammatory monocyte axis
A stimulated proinflammatory feature of leukemic progenitors facilitates their survival and immune evasion after chemotherapy.
- Open Access
- 24 September 2021
- Published by Springer Nature in Cell Research
- Vol. 31 (11) , 1148-1162
Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2pos subjects
Increasing numbers of SARS-CoV-2-positive (SARS-CoV-2pos) subjects are detected at silent SARS-CoV-2 infection stage (SSIS). Yet, SSIS represents a poorly examined time-window wherein unknown immunity patterns may contribute to the fate determination towards persistently asymptomatic or overt disease. Here, we retrieved blood samples from 19 asymptomatic and 12 presymptomatic SARS-CoV-2pos subjects, 47 age/gender-matched patients with mild or moderate COVID-19 and 27 normal subjects, and interrogated them with combined assays of 44-plex CyTOF, RNA-seq and Olink. Notably, both asymptomatic and presymptomatic subjects exhibited numerous readily detectable immunological alterations, while certain parameters including more severely decreased frequencies of CD107alow classical monocytes, intermediate monocytes, non-classical monocytes and CD62Lhi CD8+ Tnaïve cells, reduced plasma STC1 level but an increased frequency of CD4+ NKT cells combined to distinguish the latter. Intercorrelation analyses revealed a particular presymptomatic immunotype mainly manifesting as monocytic overactivation and differentiation blockage, a likely lymphocyte exhaustion and immunosuppression, yielding mechanistic insights into SSIS fate determination, which could potentially improve SARS-CoV-2 management.
- 24 September 2021
- Published by Springer Nature in Cell Research
- Vol. 31 (11) , 1148-1162
Open AccessDistinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2pos subjects
Increasing numbers of SARS-CoV-2-positive (SARS-CoV-2pos) subjects are detected at silent SARS-CoV-2 infection stage (SSIS). Yet, SSIS represents a poorly examined time-window wherein unknown immunity patterns may contribute to the fate determination towards persistently asymptomatic or overt disease. Here, we retrieved blood samples from 19 asymptomatic and 12 presymptomatic SARS-CoV-2pos subjects, 47 age/gender-matched patients with mild or moderate COVID-19 and 27 normal subjects, and interrogated them with combined assays of 44-plex CyTOF, RNA-seq and Olink. Notably, both asymptomatic and presymptomatic subjects exhibited numerous readily detectable immunological alterations, while certain parameters including more severely decreased frequencies of CD107alow classical monocytes, intermediate monocytes, non-classical monocytes and CD62Lhi CD8+ Tnaïve cells, reduced plasma STC1 level but an increased frequency of CD4+ NKT cells combined to distinguish the latter. Intercorrelation analyses revealed a particular presymptomatic immunotype mainly manifesting as monocytic overactivation and differentiation blockage, a likely lymphocyte exhaustion and immunosuppression, yielding mechanistic insights into SSIS fate determination, which could potentially improve SARS-CoV-2 management.